Search This Blog

Friday, July 12, 2019

Bayer won’t get new trial in $80M Roundup case

A U.S. District Judge has rejected Bayer’s (OTCPK:BAYRY) request for a new trial in the case of a California man who was awarded $80M by a jury after it found exposure to the company’s Roundup weedkiller caused his cancer.
Judge Chhabria, who is expected to issue a second ruling Monday on whether to reduce the damages in the case, ruled the plaintiff presented “sufficient admissible evidence” to the jury that exposure to Roundup caused his cancer.
The judge is handling the collection of hundreds of federal lawsuits involving Roundup.

Indivior loses appeal to block generic Suboxone opioid treatments

A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy’s Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents.
The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy’s did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents.
Suboxone film is applied below a patient’s tongue, where it dissolves to release two active ingredients, buprenorphine and naloxone.
It had accounted for about 80 percent of Indivior’s revenue, but the London-based company forecast declines after the U.S. Supreme Court in February allowed sales of generic equivalents, including by India-based Dr. Reddy’s.
Circuit Judge Alan Lourie wrote for a 2-1 majority that while Indivior’s patents should not be voided, it failed to show that they covered Dr. Reddy’s and Alvogen’s drying processes for their products, or a polymer that Dr. Reddy’s used.
The court also said another generic drugmaker, Teva Pharmaceutical Industries Ltd, did not show that the patent concerning the drying process should be voided.

Indivior launched the first buprenorphine-based product to treat opioid dependence in 1996. It had sought damages, as well as injunctions against the U.S. sale of infringing products, in lawsuits underlying Friday’s decision.
The dissent said Indivior’s patents should have been voided because they described methods to produce sublingual films that were already known, and were therefore “obvious.”
Indivior’s lawyers did not immediately respond to requests for comment.
Kevin Martin, a lawyer for Dr. Reddy’s, said in an email: “We’re glad that the Federal Circuit has again concluded that Dr. Reddy’s generic films are non-infringing, which will keep this low-cost treatment option on the market.”
Alvogen spokesman Halldor Kristmannsson said the company, which has offices in New Jersey, was also pleased. Teva’s lawyers did not immediately respond to requests for comment.
Indivior was separately indicted in April by a federal grand jury in Virginia for allegedly scheming to boost Suboxone film sales. The U.S. government wants Indivior to forfeit at least $3 billion.

On Thursday, Reckitt Benckiser Group Plc, which spun off Indivior in 2014, agreed with U.S. regulators to pay up to $1.4 billion to settle similar claims. Indivior said that settlement was separate from its own case.
The case is Indivior Inc et al v Dr. Reddy’s Laboratories SA et al, U.S. Federal Circuit Court of Appeals, No. 17-2587.

Federal judge orders FDA to implement 10-month deadline for e-cig applications

A U.S. federal judge on Friday ordered the Food and Drug Administration to impose a 10-month deadline for the submission of e-cigarette applications, turning the screws on companies like Juul Labs Inc whose products have come under intense scrutiny for their popularity among teenagers.
The FDA last month proposed the shorter timeline after the U.S. District Court for Maryland ruled in a lawsuit filed by anti-tobacco groups that the agency had exceeded its authority in allowing e-cigarettes to remain on the market until 2022 before companies applied for regulatory approval.
“I will impose a ten-month deadline for submissions and a one-year deadline for approval, as the FDA suggested,” U.S. Judge Paul Grimm wrote in a court order on Friday.
Before last month, the agency had proposed makers of e-cigarettes have until August 2021 to submit a formal application to keep selling their products.

But the public health and anti-tobacco groups that originated the suit countered that e-cigarette and cigar makers submit applications within 120 days.
“Today’s ruling is an important step forward for public health and validates FDA’s commitment to accelerate review of these products, particularly the ones that are most attractive to youth,” acting FDA Commissioner Ned Sharpless said.
Juul said in a statement that it was closely assessing the court’s ruling, while adding that it was fully committed to the FDA’s application process.

AI-Powered Smart Stethoscope Revolutionizing Remote Medicine

One of the most important aspects of the routine visit to the doctor’s office is the use of the stethoscope, known as auscultation. This technique allows the physician to listen to the lungs, heart, and other organs for unusual sounds that signify various conditions. Though many apps and telemedicine platforms have allowed patients to seek medical care in the comfort of their own homes, none have been able to replicate this essential in-person procedure. By recording sound and using artificial intelligence (AI), however, the unique StethoMe device has the power to add auscultation to remote healthcare.
With a startling 80% of lung and heart sounds being misdiagnosed and improperlytreated in the WHO European region alone, StethoMe’s AI capabilities present as an attractive way to make these interpretations more consistent. In addition, the device has the potential to greatly reduce the number of unnecessary doctor visits. 70% of in-person visits are deemed unneeded and often end up exposing patients to other viruses while in the medical setting. By offering clinically supported AI in a stethoscope that can be used at home, StethoMe has the power to reduce the number of avoidable trips taken to medical centers.

What is the StethoMe Smart Stethoscope?

StethoMe is a small, wireless stethoscope that the consumer can use anywhere to conduct an auscultation. The device is paired with a smartphone app that tells the user where to properly position the stethoscope, which then collects audio from the procedure. This recording is decoded by AI that is trained to analyze respiratory and heart sounds. The processed information is sent to a physician, who then interprets the sounds as if they had the stethoscope pressed to their patient.
Using the StethoMe’s physician platform, the doctor is able to see in depth characterization from the AI, which is trained to identify wheezing and other abnormalities. In addition to the auscultation audio, StethoMe also provides the physician with a waveform of the audio. This adds a novel dimension to the examination, allowing the provider to identify visual characteristics associated with different symptoms.
stethoscope
On the patient’s end, they simply see a green light that indicates normal breathing sounds, or a red light that indicates abnormality. Wojciech Radomski, StethoMe’s CEO, claims this was done to leave the diagnosis in the doctor’s hands rather than having the patient falsely identify conditions.
“We only present them red or green points, which means that based on this information, they can know if there is anything wrong or not,” said Radomski in an interview with DocWire News. “We do not want users to Google their symptoms and treat themselves, we want them to connect with doctors.”

The Artificial Intelligence Behind the StethoMe

Both the device and the AI algorithm for respiratory auscultation recently received CE Certification after performing comparatively to doctors in a study published in the European Journal of Pediatrics. What enables the device to be so effective is the accurate detection of basic respiratory sounds: wheezing, rhonchi (low-pitched wheezes), and coarse and fine crackles. The AI interprets the patient’s breathing sounds and selects segments that best represent each of these four abnormalities for the physician to see.
“These four categories of sounds are the basic sounds for oral lung diseases,” noted Radomski. “Based on these sounds, doctors can diagnose different lung diseases like asthma, COPD, cystic fibrosis, and all the others. We are not focusing on any particular disease. By recognizing those basic categories of the sounds, the device can be used for any lung disease.”
stethome
Sławomir Kmak, Business Development Director at StethoMe, noted that their AI algorithm was trained using over 12,000 auscultation sounds obtained using their device. There was no pre-existing “gold standard” for such sounds, therefore their team had to gather this data on their own. After consulting with several physicians, pulmonologists, physicists, and acousticians from their partner hospitals and institutes, StethoMe was able to produce an accurate algorithm for respiratory auscultations. Kmak noted that the device can be used as a traditional stethoscope as well, with a port to plug in headphones.

Revolutionizing Remote Healthcare

After receiving many awards for their product, StethoMe now has sights set on expansion and further development of their algorithm. The AI is currently approved for observing respiratory sounds in children, but Radomski claims that adult AI will be incorporated by the end of the year.
“We started by creating the device for children — as a small company we had to focus on one target group. Currently the device [can receive sounds] from children and adults, but our AI algorithms are certified for children only. Right now, we are expanding our data base. We already have recordings of adults, but we need to gather a bit more of them to re-certify the algorithms so they will work on both children and adults.”stethome
He added that StethoMe has already developed AI that analyzes heart sounds for abnormalities as well, and that certification for this solution is to be expected by the end of the year.
Regarding commercial availability, StethoMe plans to initially launch their product in Europe but to find business partners for international expansion as well. The company also has a multi-national, multi-centered clinical study underway that is designed to once again prove the devices efficacy.
“Our dream is to put StethoMe in every home like thermometers are today,” concluded Radomski. “We want to be the best company when it comes to recognizing any abnormalities in the lungs and heart in the next couple of years.”

The Story Behind StethoMe

The initial steps towards building StethoMe were taken by Radomski and co-founders Paweł Elbanowski and Marcin Szajek, who Radomski has been running an IT company with for over 10 years.
“We decided that we want to use our experience in the IT world and connect it with medicine. In fact, I came to idea that we could use our experience, the money that we earned, and the connections that we have in creating something bigger that will help more people in the world,” said Radomski.
StethoMeRadomski and his coworkers listed a sponsored post to Facebook seeking doctors who had problems they felt IT could solve, at which point they came across their new co-founders. Honorata Hafke-Dys and Jędrzej Kocińsk were not physicians, but were PhD’s from the University from Acoustics that presented this real-life problem Radomski and colleagues could solve with their IT expertise. At the time, Hafke-Dys and Kocińsk were parents of children who frequently had respiratory infections. This inspired the two to create a remote stethoscope that could help parents who were in similar circumstances. Together, these five created what is now StethoMe.

Perrigo Completes Acquisition Of Ranir, Raises Guidance

Perrigo Company plc (NYSE; TASE: PRGO) announced the successful completion of its acquisition of Ranir Global Holdings LLC (“Ranir”), the leading global store brand supplier of oral self-care products, for $750 million in cash. This transaction advances Perrigo’s transformation to a consumer-focused, self-care company while enhancing its position as a global leader in consumer self-care solutions.
Perrigo CEO and President Murray S. Kessler commented, “We are pleased to announce the successful completion of this bolt-on acquisition and look forward to welcoming the talented Ranir team to the Perrigo family. Our combined scale, global presence, innovation pipelines, and shared self-care strategies immediately accelerates growth and enhances our robust store brand portfolio. We look forward to providing customers and consumers with our expanded product offerings in this adjacent self-care category.”
Kessler continued, “As stated at our investor conference, the successful closing of the Ranir acquisition represented upside to our 2019 guidance. Based on today’s closing we are adjusting our 2019 adjusted diluted EPS guidance range up by 10 cents.”

An ‘EpiPen’ for spinal cord injuries

An injection of nanoparticles can prevent the body’s immune system from overreacting to trauma, potentially preventing some spinal cord injuries from resulting in paralysis.
The approach was demonstrated in mice at the University of Michigan, with the nanoparticles enhancing healing by reprogramming the aggressive immune cells–call it an “EpiPen” for trauma to the central nervous system, which includes the brain and spinal cord.
“In this work, we demonstrate that instead of overcoming an immune response, we can co-opt the immune response to work for us to promote the therapeutic response,” said Lonnie Shea, the Steven A. Goldstein Collegiate Professor of Biomedical Engineering.
Trauma of any kind kicks the body’s immune response into gear. In a normal injury, immune cells infiltrate the damaged area and clear debris to initiate the regenerative process.
The central nervous system, however, is usually walled off from the rough-and-tumble of immune activity by the blood-brain barrier. A spinal cord injury breaks that barrier, letting in overzealous immune cells that create too much inflammation for the delicate neural tissues. That leads to the rapid death of neurons, damage to the insulating sheaths around nerve fibers that allow them to send signals, and the formation of a scar that blocks the regeneration of the spinal cord’s nerve cells.
All of this contributes to the loss of function below the level of the injury. That spectrum includes everything from paralysis to a loss of sensation for many of the 12,000 new spinal injury patients each year in the United States.
Previous attempts to offset complications from this immune response included injecting steroids like methylprednisolone. That practice has largely been discarded since it comes with side effects that include sepsis, gastrointestinal bleeding and blood clots. The risks outweigh the benefits.
But now, U-M researchers have designed nanoparticles that intercept immune cells on their way to the spinal cord, redirecting them away from the injury. Those that reach the spinal cord have been altered to be more pro-regenerative.
With no drugs attached, the nanoparticles reprogram the immune cells with their physical characteristics: a size similar to cell debris and a negative charge that facilitates binding to immune cells. In theory, their nonpharmaceutical nature avoids unwanted side effects.
With fewer immune cells at the trauma location, there is less inflammation and tissue deterioration. Second, immune cells that do make it to the injury are less inflammatory and more suited to supporting tissues that are trying to grow back together.
“Hopefully, this technology could lead to new therapeutic strategies not only for patients with spinal cord injury but for those with various inflammatory diseases,” said Jonghyuck Park, a U-M research fellow working with Shea.
Previous research has shown success for nanoparticles mitigating trauma caused by the West Nile virus and multiple sclerosis, for example.
“The immune system underlies autoimmune disease, cancer, trauma, regeneration–nearly every major disease,” Shea said. “Tools that can target immune cells and reprogram them to a desired response have numerous opportunities for treating or managing disease.”
###
The research, published in the current issue of Proceedings of the National Academy of Sciences, was supported by The National Institutes of Health. Shea is also the William and Valerie Hall Chair of Biomedical Engineering and a professor of chemical engineering.

Coping strategy therapy for family dementia carers works long-term

A programme of therapy and coping strategies for people who care for family members with dementia successfully improves the carers’ mental health for at least a six-year follow-up, finds a UCL study.
Carers who took part in the programme were five times less likely to have clinically significant depression than carers who were not offered the therapy, according to the findings published in the British Journal of Psychiatry.
The intervention has also been shown to be cost-effective in a prior study.
“Taking care of a family member with dementia can be immensely difficult, particularly as their condition deteriorates and they may not appreciate their carer, so close to four in 10 family carers experience depression of anxiety,” said Professor Gill Livingston (UCL Psychiatry), the trial’s principal investigator.
“We now can offer an evidence-based approach to support their mental health in the short- and long-term, which benefits both the carer and the person they’re caring for.”
The START (STrAtegies for RelaTives) programme is delivered by psychology graduates, trained and supervised by the research team, instead of qualified clinicians, making it easy to implement in many settings.
Those delivering the therapy work with carers to develop coping strategies, supporting them to manage their own wellbeing in the long run without needing further therapy sessions. Carers received eight sessions during which there is an emphasis on planning for the future and accessing further support if needed.
260 family carers took part in the trial, most of whom were caring for a family member who had only recently been diagnosed with dementia. 173 of the participants were enrolled in the START programme for a two-year period and the other 87 were randomly assigned to a control group that did not receive the intervention.
Six years after receiving the therapy, the carers who were in the START programme had significantly fewer symptoms of depression and anxiety, and the researchers say the therapy programme appeared to be both preventative and improve existing mental ill-health.
Patient-related costs were close to three times lower among the families in the START programme (averaging £5759 for those in START versus £16 964 in the control group in year six), which the researchers say is likely due to the carers being more able to cope and provide care for their loved one.
The difference of patient-related costs did not reach statistical significance, but the researchers say this is due to the fact medical costs can be very large and variable. However, their results do strongly suggest the programme is not only cost-effective, but could save money for healthcare services.
“We’ve designed our programme to keep costs low, and our results suggest it could actually result in cost savings in the longer term as dementia patients will have fewer costly medical problems if their family carer is healthy and supported,” said Professor Livingston.
The START team have developed manuals to make it easier for any healthcare provider to deliver the intervention, and plan to provide accredited training at UCL in the near future. Alzheimer’s Society are supporting the team to explore different options for getting the intervention further implemented into practice, and provided funding to make cultural adaptations to widen access to minority ethnic groups. The training manuals are also available in Japanese and Spanish, and are currently being translated into Urdu.
James Pickett, Head of Research at Alzheimer’s Society, said: “Being a carer can be a gruelling job; physically and emotionally demanding, 24 hours a day and often done purely out of love. Unfortunately, depression and anxiety can be an inevitable side effect – with 90% of carers telling us they experience stress and anxiety several times a week. Yet, for the 700,000 carers across the UK, many receive little or no support, despite NICE guidelines recommending that they do.
“This is a major breakthrough. We are absolutely thrilled to see this monumental evidence that START is clinically effective at reducing depression and anxiety in carers, and that the effects can still be seen six years later. This could turn the tide for carers and we would love for it to be available to all people who care for someone with dementia. Alzheimer’s Society is delighted to be supporting the further development and implementation of the START programme so as many people can benefit as possible.”
Shirley Nurock, a former carer who worked on the project as a liaison with the families, commented: “After my husband developed Alzheimer’s disease in his 50s, I spent 15 years caring for him. I was stressed and anxious throughout, feeling powerless as I watched him deteriorate, torn between prioritizing care for him, seeing my children through their teenage years and keeping an eye on my ageing parents.
“I can see now that an intervention like START would have allayed some of my earlier anxieties by giving me appropriate practical information, advice about services, support, coping strategies, and helping me learn how to relax. Learning that it can have such long-term effects is extremely encouraging.”
###
The project is funded by the National Institute for Health Research Health Technology Assessment programme.